Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia

M. Lazzarino, E. Morra, E. Brusamolino, D. Inverardi, G. Castelli, S. Merante, C. Bernasconi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

From 1975 to 1981, 92 patients with newly diagnosed Ph'-positive chronic granulocytic leukemia entered two consecutive studies. The initial trial tested the efficacy of hydroxyurea (HU) as single agent in 45 consecutive patients. In an effort to improve results obtained with HU alone, from 1978 to 1981, 47 new patients entered a second trial, which consisted of a continuous treatment with a combination of HU and 6-mercaptopurine (6-MP), at doses adjusted so as to maintain the leukocyte counts between 4 and 12 x 109/L. The aim of this second study was to prolong the duration of chronic phase (CP) by the addition of 6-MP to HU and by a stricter continuous control of the size of the total granulocytic mass (TGM). Both regimens were well tolerated. Median duration of CP was 43 months in Study I and 41 months in Study II. Median survival was 51.5 months and 45 months respectively. These data indicate that neither the addition of 6-MP to HU alone, nor the effort to keep a smaller TGM, play a substantial role in postponement of blastic transformation in CGL.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume9
Issue number1
Publication statusPublished - 1986

Fingerprint

6-Mercaptopurine
Hydroxyurea
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Leukocyte Count
Survival

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lazzarino, M., Morra, E., Brusamolino, E., Inverardi, D., Castelli, G., Merante, S., & Bernasconi, C. (1986). Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia. American Journal of Clinical Oncology: Cancer Clinical Trials, 9(1), 45-49.

Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia. / Lazzarino, M.; Morra, E.; Brusamolino, E.; Inverardi, D.; Castelli, G.; Merante, S.; Bernasconi, C.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 9, No. 1, 1986, p. 45-49.

Research output: Contribution to journalArticle

Lazzarino, M, Morra, E, Brusamolino, E, Inverardi, D, Castelli, G, Merante, S & Bernasconi, C 1986, 'Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 9, no. 1, pp. 45-49.
Lazzarino, M. ; Morra, E. ; Brusamolino, E. ; Inverardi, D. ; Castelli, G. ; Merante, S. ; Bernasconi, C. / Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1986 ; Vol. 9, No. 1. pp. 45-49.
@article{9b006834eb9341988877f9db9381b730,
title = "Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia",
abstract = "From 1975 to 1981, 92 patients with newly diagnosed Ph'-positive chronic granulocytic leukemia entered two consecutive studies. The initial trial tested the efficacy of hydroxyurea (HU) as single agent in 45 consecutive patients. In an effort to improve results obtained with HU alone, from 1978 to 1981, 47 new patients entered a second trial, which consisted of a continuous treatment with a combination of HU and 6-mercaptopurine (6-MP), at doses adjusted so as to maintain the leukocyte counts between 4 and 12 x 109/L. The aim of this second study was to prolong the duration of chronic phase (CP) by the addition of 6-MP to HU and by a stricter continuous control of the size of the total granulocytic mass (TGM). Both regimens were well tolerated. Median duration of CP was 43 months in Study I and 41 months in Study II. Median survival was 51.5 months and 45 months respectively. These data indicate that neither the addition of 6-MP to HU alone, nor the effort to keep a smaller TGM, play a substantial role in postponement of blastic transformation in CGL.",
author = "M. Lazzarino and E. Morra and E. Brusamolino and D. Inverardi and G. Castelli and S. Merante and C. Bernasconi",
year = "1986",
language = "English",
volume = "9",
pages = "45--49",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Hydroxyurea and 6-mercaptopurine in the treatment of chronic granulocytic leukemia

AU - Lazzarino, M.

AU - Morra, E.

AU - Brusamolino, E.

AU - Inverardi, D.

AU - Castelli, G.

AU - Merante, S.

AU - Bernasconi, C.

PY - 1986

Y1 - 1986

N2 - From 1975 to 1981, 92 patients with newly diagnosed Ph'-positive chronic granulocytic leukemia entered two consecutive studies. The initial trial tested the efficacy of hydroxyurea (HU) as single agent in 45 consecutive patients. In an effort to improve results obtained with HU alone, from 1978 to 1981, 47 new patients entered a second trial, which consisted of a continuous treatment with a combination of HU and 6-mercaptopurine (6-MP), at doses adjusted so as to maintain the leukocyte counts between 4 and 12 x 109/L. The aim of this second study was to prolong the duration of chronic phase (CP) by the addition of 6-MP to HU and by a stricter continuous control of the size of the total granulocytic mass (TGM). Both regimens were well tolerated. Median duration of CP was 43 months in Study I and 41 months in Study II. Median survival was 51.5 months and 45 months respectively. These data indicate that neither the addition of 6-MP to HU alone, nor the effort to keep a smaller TGM, play a substantial role in postponement of blastic transformation in CGL.

AB - From 1975 to 1981, 92 patients with newly diagnosed Ph'-positive chronic granulocytic leukemia entered two consecutive studies. The initial trial tested the efficacy of hydroxyurea (HU) as single agent in 45 consecutive patients. In an effort to improve results obtained with HU alone, from 1978 to 1981, 47 new patients entered a second trial, which consisted of a continuous treatment with a combination of HU and 6-mercaptopurine (6-MP), at doses adjusted so as to maintain the leukocyte counts between 4 and 12 x 109/L. The aim of this second study was to prolong the duration of chronic phase (CP) by the addition of 6-MP to HU and by a stricter continuous control of the size of the total granulocytic mass (TGM). Both regimens were well tolerated. Median duration of CP was 43 months in Study I and 41 months in Study II. Median survival was 51.5 months and 45 months respectively. These data indicate that neither the addition of 6-MP to HU alone, nor the effort to keep a smaller TGM, play a substantial role in postponement of blastic transformation in CGL.

UR - http://www.scopus.com/inward/record.url?scp=0022621376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022621376&partnerID=8YFLogxK

M3 - Article

C2 - 3513537

AN - SCOPUS:0022621376

VL - 9

SP - 45

EP - 49

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 1

ER -